Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A
NCT04759131
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
74
Enrollment
INDUSTRY
Sponsor class
Conditions
Hemophilia A
Interventions
DRUG:
efanesoctocog alfa (BIVV001)
Sponsor
Bioverativ, a Sanofi company